VIA
AVBP icon

Virtus Investment Advisers’s ArriVent BioPharma AVBP Stock Holding History

Virtus Investment Advisers’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258K Buy
11,165
+271
+2% +$6.12K 0.07% 308
2025
Q4 		$219K Buy
10,894
+6,078
+126% +$127K 0.06% 364
2025
Q3 		$88.9K Buy
4,816
+837
+21% +$16.4K 0.03% 429
2025
Q2 		$86.6K Sell
3,979
-2,369
-37% -$49.2K 0.03% 398
2025
Q1 		$117K Buy
+6,348
New +$155K 0.03% 397

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Virtus Investment Advisers's AVBP Position: Q1 2026 in Review

Virtus Investment Advisers increased its ArriVent BioPharma (AVBP) stake by 2.5% in Q1 2026, buying an estimated $6.12K and bringing the position to 11,165 shares worth $258K. The position accounts for 0.07% of the portfolio, ranked #308.

Virtus Investment Advisers first reported a position in AVBP in Q1 2025 and has held it in 5 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Virtus Investment Advisers held 11,165 shares of ArriVent BioPharma worth $258K as of Q1 2026.
  • Virtus Investment Advisers bought 271 ArriVent BioPharma shares in Q1 2026, an estimated $6.12K.
  • ArriVent BioPharma made up 0.07% of Virtus Investment Advisers's portfolio in Q1 2026, its #308 holding.
  • Virtus Investment Advisers first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 5 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.